Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pender & Associates Ltd .
Filed returns
87
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2020 | Pender & Associates Ltd | Health | Ireland's health diagnostics approach (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2020 | Pender & Associates Ltd | Health | Ireland's COVID-19 response and testing (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2020 | Pender & Associates Ltd | Health | Engagement with Dept. of Health re. use of ethanol for hand sanitiser (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Pender & Associates Ltd | Health | Public health and alcohol (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2019 | Pender & Associates Ltd | Health | Atrial Fibrillation Institute - Mater Private Hospital (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2019 | Pender & Associates Ltd | Health | Enhance access and affordability of medicines in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Pender & Associates Ltd | Health | Enhance access and affordability of medicines in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2019 | Pender & Associates Ltd | Health | Enhance access and affordability of medicines (Public policy or programme) | 269 | On lobbying.ie |
| May–Aug 2019 | Pender & Associates Ltd | Health | Enhance access and affordability of medicines (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2019 | Pender & Associates Ltd | Health | Enhance access and affordability of medicines (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2019 | Pender & Associates Ltd | Health | Public health and alcohol (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2019 | Pender & Associates Ltd | Health | Public health and alcohol (Public policy or programme) | 8 | On lobbying.ie |
| May–Aug 2019 | Pender & Associates Ltd | Health | Enhance access and affordability of medicines (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2019 | Pender & Associates Ltd | Health | Consultant recruitment and retention crisis (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2019 | Pender & Associates Ltd | Health | Engagement on medicine policy reform (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Pender & Associates Ltd | Health | Breifing in relation to migraine as part of the National Clinical Programme for Neurology (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2019 | Pender & Associates Ltd | Health | Meeting request on medicine procurement and pricing (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2018 | Pender & Associates Ltd | Health | Meeting request to Ambassador Hackett (Irish representation to EU) (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pender & Associates Ltd | Health | Meeting request (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Pender & Associates Ltd | Health | Public health policies and best practice, in particular regarding anaphylaxis (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2017 | Pender & Associates Ltd | Health | Emergency medicine training for anaphylaxis/adrenaline medication; biosimilars policy; SPC waiver. (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Pender & Associates Ltd | Health | Biosimilar policy and national medicines strategy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2017 | Pender & Associates Ltd | Health | Meeting request (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2017 | Pender & Associates Ltd | Health | Introduction of National Medicines Policy, National Medicines Office, and introduction of biosimilars consultation (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2017 | Pender & Associates Ltd | Health | Supplementary Protection Certificate Manufacturing Waiver and biosimilars policy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2017 | Pender & Associates Ltd | Health | Medicines policy and biosimilars (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2016 | Pender & Associates Ltd | Health | Medicines policy (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2016 | Pender & Associates Ltd | Health | Engagement on Antimicrobial Resistance policy (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2016 | Pender & Associates Ltd | Health | Review/inform national drugs policy, to include additional treatment options (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2016 | Pender & Associates Ltd | Health | Medicines policy (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2016 | Pender & Associates Ltd | Health | Inform national drugs policy in relation to treatment methods (Legislation) | 4 | On lobbying.ie |
| May–Aug 2016 | Pender & Associates Ltd | Health | Medicines policy (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2016 | Pender & Associates Ltd | Health | To inform on national drugs policy and the addiction treatment method of Suboxone (Legislation) | 2 | On lobbying.ie |
| May–Aug 2016 | Pender & Associates Ltd | Health | Medicines policy (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2016 | Pender & Associates Ltd | Health | EU Directive on Medical Technologies (Legislation) | 1 | On lobbying.ie |
| May–Aug 2016 | Pender & Associates Ltd | Health | Engagement on Antimicrobial Resistance policy (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2015 | Pender & Associates Ltd | Health | Engagement with policy makers to achieve savings/reforms in the Government's/HSE's medicines spending programme (Public policy or programme) | 10 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 87 | 100.0% |